SecBot SecBot

TLX

Telix Pharmaceuticals Ltd
Nasdaq· Pharmaceutical Preparations· Inc. C3· CIK 0002007191 Biotech & Drug Discovery
$8.92 −0.31 (−3.36%)
Nov 16 4:00 PM ET · prev $9.23
Market cap
$3.2B
Mid cap
Median target
🔒 Subscribers only
1 year
−2.6%
from $9.16 · Nov 17
30 days
−16.9%
from $10.74
52-week range
$6.41–12.83
−30% from high · low Feb 18
Avg volume 20D
335.1K
Oct 21 spike 874.5K
Short interest
270.6K
≈0.1% of shares · −23.3%
Days to cover
1.0
at average volume
Insider net
+$1.0M
2 buyers · 0 sellers · 12 mo
New fund stakes
0
Q3 2026 13F · 0 exits
Filing reports
12
analyzed by SecBot
SecBot read BULLISH 12 reports · 90 days
Balance 0 bearish · 10 bullish · 2 neutral oldest → newest, height = score
Avg score ·High conf. 12/12

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersBULLISH

    2 insiders bought $1.0M. No open-market sales.

  • InstitutionsBULLISH

    Q3 2026: 9 added (0 new), 4 trimmed or exited.

  • Short sellersCOVERING

    Short interest −23.3% to 270.6K shares. 1.0 days to cover, ≈0.1% of shares.

  • TrendDOWNTREND

    16% below its 50-day average.

Who's buying

13F· Q3 2026
0
new positions
0
exits
FundMoveSharesValue
BLAIR WILLIAM & CO/ILDOUBLED480,685$5.3M
UBS Group AGTRIM97,163$1.1M
Orion Porfolio Solutions, LLCDOUBLED48,757$534.9K
MARSHALL WACE, LLPNEAR_EXIT37,502$411.4K
MORGAN STANLEYNEAR_EXIT29,941$328.5K
BNP PARIBAS FINANCIAL MARKETSADD28,500$312.6K
OSAIC HOLDINGS, INC.DOUBLED13,794$151.3K
NATIXISTRIM7,387$81.4K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

Last action Oct 2026

Fresh Price Targets

Analyst price targets updated within the last 24 hours are for subscribers only.

Subscribe for Full Access
Recent actions
DateFirmActionRating
Oct 21, 2026Wedbush
REITERATE
REITERATEOutperform
Sep 25, 2026HC Wainwright & Co.
REITERATE
REITERATEBuy
Sep 23, 2026Wedbush
REITERATE
REITERATEOutperform
Sep 15, 2026HC Wainwright & Co.
REITERATE
REITERATEBuy
Sep 14, 2026Wedbush
REITERATE
REITERATEOutperform
Sep 2, 2026HC Wainwright & Co.
REITERATE
REITERATEBuy

Insider ledger

Form 4
$1.0M
bought · 2 insiders
$0
sold · 0 insiders
DateInsiderTypeValue
Sep 7, 2026
Smith Darren Charlton
Group Chief Financial Officer
Sep 7, 2026
BUY$20.0K
Apr 29, 2026
Behrenbruch Christian
MD & Group CEO
Apr 29, 2026
BUY$497.2K
Apr 28, 2026
Behrenbruch Christian
MD & Group CEO
Apr 28, 2026
BUY$499.6K
Mar 29, 2026
Smith Darren Charlton
Group Chief Financial Officer
Mar 29, 2026
EXERCISE1,111 sh

Earnings setup

Estimates

Revision history: 🔒 Fresh data, subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data, subscribers only
Next Q🔒 Fresh data, subscribers only
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only

Washington

Corporate Lobbying

12 lobbying filings and 0 bills this company lobbies on, with spend, stage and how each bill touches it, are for subscribers.

Subscribe for Full Access

Short side

FINRA· Oct 30, 2026
270,623
shares short
-23.3%
vs prior settlement
1.0
days to cover
≈0.1%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
5 drugs tracked · Drug pipeline →
Recent

SecBot reports

12 filings · 15 press releases · 9 bullish · 0 bearish · 3 neutral
All TLX filing & press-release reports (27)